100 Clinical Results associated with CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University)

100 Translational Medicine associated with CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University)

100 Patents (Medical) associated with CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University)

Literatures (Medical) associated with CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University)

Biomolecules and Biomedicine

CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar

Review

Author: Liu, Min-Ling ; Fang, Shuo ; Chen, Kun ; Wang, Jian-Cheng

Adoptive cell therapy (ACT) has been demonstrated to be one of the most promising cancer immunotherapy strategies due to its active antitumor capabilities in vivo. Engineering T cells to overexpress chimeric antigen receptors (CARs), for example, has shown potent efficacy in the therapy of some hematologic malignancies. However, the efficacy of chimeric antigen receptor T cell (CAR-T) therapy against solid tumors is still limited due to the immunosuppressive tumor microenvironment (TME) of solid tumors, difficulty in infiltrating tumor sites, lack of tumor-specific antigens, antigen escape, and severe side effects. In contrast, macrophages expressing CARs (CAR-macrophages) have emerged as another promising candidate in immunotherapy, particularly for solid tumors. Now at its nascent stage (with only one clinical trial progressing), CAR-macrophage still shows inspiring potential advantages over CAR-T in treating solid tumors, including more abundant antitumor mechanisms and better infiltration into tumors. In this review, we discuss the relationships and differences between CAR-T and CAR-macrophage therapies in terms of their CAR structures, antitumor mechanisms, challenges faced in treating solid tumors, and insights gleaned from clinical trials and practice for solid tumors. We especially highlight the potential advantages of CAR-macrophage therapy over CAR-T for solid tumors. Understanding these relationships and differences provides new insight into possible optimization strategies of both these two therapies in solid tumor treatment.

100 Deals associated with CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glioblastoma	Preclinical	CN	Shandong Xingrui Biotechnology Co., Ltd.	03 Aug 2022
Glioblastoma	Preclinical	CN	Shandong University	03 Aug 2022
Glioblastoma	Preclinical	CN	Qilu Pharmaceutical Co., Ltd.	03 Aug 2022
Glioblastoma	Preclinical	CN	Yinfeng Biological Engineering Group Co. Ltd.	03 Aug 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CD133 Targeted CAR-Macrophage(Qilu Pharmaceutical/Shandong Xingrui Biotechnology/Yinfeng Biological Engineering Group/Shandong University)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation